Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?

Schizophrenia Research

Volumn 125, Issue 2-3, 2011, Pages 278-283

  Kulkarni, Jayashri ^a   de Castella, Anthony ^a   Headey, Barbara ^a   Marston, Natasha ^a   Sinclair, Kelly ^a   Lee, Stuart ^a   Gurvich, Caroline ^a   Fitzgerald, Paul B ^a   Burger, Henry ^b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Men; Oestrogen estrogen; Schizophrenia; Sex hormones

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; ESTRADIOL VALERATE; ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; MOOD STABILIZER; OLANZAPINE; PLACEBO; PRASTERONE SULFATE; PROLACTIN; RISPERIDONE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD SAMPLING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; FOLLICLE STIMULATING HORMONE; HUMANS; MALE; MIDDLE AGED; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TESTOSTERONE;

EID: 78951481648     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.10.009     Document Type: Article

References (37)

1. Akhondzadeh S., Nejatisafa A.A., Amini H., Mohammadi M.R., Larijani B., Kashani L., Raisi F., Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2003, 27(6):1007-1012.
2. Akhondzadeh S., Rezaei F., Larijani B., Nejatisafa A.-A., Kashani L., Abbasi S.H. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr. Res. 2006, 84(2-3):405-410.
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV 1994, American Psychiatric Association, Washington, DC. 4th ed.
4. Arnold S.E. Estrogen for refractory aggression after traumatic brain injury. Am. J. Psychiatry 1993, 150(10):1564-1565.
5. Bergemann N., Parzer P., Runnebaum B., Resch F., Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 2007, 37(10):1427-1436.
6. Cornil C.A., Ball G.F., Balthazart J. Functional significance of the rapid regulation of brain estrogen action: where do the estrogens come from?. Brain Res. 2006, 1126(1):2-26.
7. Cyr M., Calon F., Morissette M., Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J. Psychiatry Neurosci. 2002, 27(1):12-27.
8. De Lignieres B., Basdevant A., Thomas G., Thalabard J.C., Mercier-Bodard C., Conard J., Guyene T.T., Mairon N., Corvol P., Guy-Grand B., et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J. Clin. Endocrinol. Metab. 1986, 62(3):536-541.
9. Del Rio G., Velardo A., Zizzo G., Avogaro A., Cipolli C., Della Casa L., Marrama P., MacDonald I.A. Effect of estradiol on the normal sympathoadrenal response to mental stress in normal men. J. Clin. Endocrinol. Metab. 1994, 79(3):836-840.
10. Drake R.J., Dunn G., Tarrier N., Bentall R.P., Haddock G., Lewis S.W. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J. Clin. Psychiatry 2007, 68(1):81-86.
11. Expert consensus panel. Optimising pharmacological treatment of psychotic disorders. J. Clin. Psychiatry' 2003, 64(Supple 12):26.
12. Garcia-Segura L.M., Azcoitia I., DonCarlos L.L. Neuroprotection by estradiol. Prog. Neurobiol. 2001, 63(1):29-60.
13. Gillies, G. E., & McArthur, S., 2010. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev, 62(2), 155-198.
14. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28(Supplement 2):17-54.
15. Häfner H., Behrens S., De Vry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res. 1991, 38(2):125-134.
16. Hall K.A., Keks N.A., O'Connor D.W. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int. Psychogeriatr. 2005, 17(02):165-178.
17. Hedlund P.O., Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. Urology 2000, 55(3):328-332.
18. Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 2004, 65(7):932-939.
19. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
20. Kirschbaum C., Schommer N., Federenko I., Gaab J., Neumann O., Oellers M., Rohleder N., Untiedt A., Hanker J., Pirke K., Hellhammer D. Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men. J. Clin. Endocrinol. Metab. 1996, 81(10):3639-3643.
21. Ko Y.-H., Jung S.-W., Joe S.-H., Lee C.-H., Jung H.-G., Jung I.-K., Kim S.-H., Lee M.-S. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology 2007, 32(4):385-391.
22. Kulkarni J., de Castella A., Smith D., Taffe J., Keks N., Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 1996, 20(3):247-252.
23. Kulkarni J., de Castella A., Taffe J. Clinical adjunctive estrogen trial in men with schizophrenia: A pilot study. Schizophr. Res. 1999, 36(1-3):286.
24. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen - a potential treatment for schizophrenia. Schizophr. Res. 2001, 48(1):137-144.
25. Kulkarni J., de Castella A., Fitzgerald P.B., Gurvich C.T., Bailey M., Bartholomeusz C., Burger H. Estrogen in severe mental illness: A potential new treatment approach. Arch. Gen. Psychiatry 2008, 65(8):955-960.
26. Kyomen H.H., Satlin A., Hennen J., Wei J.Y. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-serve dementia: Result from a short-term randomized, double-blind trial. Am. J. Geriatr. Psychiatry 1999, 7(4):339.
27. Kyomen H.H., Hennen J., Gottlieb G.L., Wei J.Y. Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia. Am. J. Psychiatry 2002, 159(7):1225-1227.
28. Lobo R.A. Estrogen replacement: the evolving role of alternative delivery systems. Introduction. Am. J. Obstet. Gynecol. 1995, 173(3, Part 2):981.
29. Maurer K., Häfner H. Methodological aspects of onset assessment in schizophrenia. Schizophr. Res. 1995, 15(3):265-276.
30. Pallanti S., Quercioli L., Pazzagli A. Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Am. J. Psychiatry 1997, 154(6):792-798.
31. Pérez-Neri I., Ramírez-Bermúdez J., Montes S., Ríos C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res. 2006, 31(10):1279-1294.
32. Rössler W., Joachim Salize H., van Os J., Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol. 2005, 15(4):399-409.
33. Sayed Y., Taxel P. The use of estrogen therapy in men. Curr. Opin. Pharmacol. 2003, 3(6):650-654.
34. Seeman M.V. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 1996, 21(2):123-127.
35. Sumner B.E., Fink G. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain. Brain Res. Mol. Brain Res. 1998, 59(2):205-214.
36. Taherianfard M., Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J. Med. Sci. 2004, 58(1):3-9.
37. Tollefson G.D., Andersen S.W. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. J. Clin. Psychiatry 1999, 60(Suppl 5):23-29.